(54 days)
Not Found
No
The device description details a standard automated immunoassay system based on chemiluminescence and competitive binding. There is no mention of AI, ML, or any computational analysis beyond standard data processing for calculating results from relative light units. The performance studies and metrics are typical for a quantitative immunoassay.
No.
This device is an in vitro diagnostic (IVD) device used for the quantitative determination of folate, not for treating a disease or condition.
Yes
The device is described as being for "quantitative determination of folate in serum or EDTA plasma and red blood cells," which is a measurement used to aid in disease diagnosis or health status assessment.
No
The device description clearly outlines a competitive immunoassay using direct chemiluminescent technology, involving physical reagents (Lite Reagent, Solid Phase, Reagent 1, Reagent 2), sample handling steps (dispensing, incubation, separation, aspiration, washing), and detection of relative light units (RLUs). This is a hardware-based laboratory assay system, not a software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states "For the quantitative determination of folate in serum or EDTA plasma and red blood cells". This indicates that the device is used to analyze samples taken from the human body (in vitro) to provide information about a person's health status (diagnostic).
- Device Description: The description details a laboratory assay process involving "patient sample" and "calibrators, quality control samples, and patient samples". This confirms it's designed for testing biological specimens outside of the body.
- Performance Studies: The performance studies describe testing "serum and red blood cell folate samples" and "serum samples" and "red blood cell samples" to determine performance characteristics. This further supports its use in analyzing human biological samples.
The core function of the device is to perform a test on biological samples to measure a specific analyte (folate) for diagnostic purposes, which is the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
For the quantitative determination of folate in serum or EDTA plasma and red blood cells using the Folate BA (Biotin Avidin) assay on the Chiron Diagnostics ACS:180® Automated Chemiluminescence Systems.
Product codes
CGN, JIS
Device Description
Folate, with vitamin B12, is essential for DNA synthesis, which is required for normal red blood cell maturation. Humans obtain folate from dietary sources including fruits, green and leafy vegetables, yeast, and organ meats. Folate is absorbed through the small intestine and stored in the liver.
Low folate intake, malabsorption as a result of qastrointestinal diseases, pregnancy, and drugs such as phenytoin are causes of folate deficiency. Folate deficiency is also associated with chronic alcoholism. Folate and vitamin B12 deficiency impair DNA synthesis, causing macrocytic anemias. These anemias are characterized by abnormal maturation of red blood cell precursors in the bone marrow, the presence of megaloblasts, and decreased red blood cell survival.
Since both folate and vitamin B12 deficiency can cause macrocytic anemia, appropriate treatment depends on the differential diagnosis of the deficiency. Serum folate measurement provides an early index of folate status. However, folate is much more concentrated in red blood cells than in serum so the red blood cell folate measurement more closely reflects tissue stores. Red blood cell folate concentration is considered the most reliable indicator of folate status.
The Chiron Diagnostics ACS:180 Folate assay is a competitive immunoassay using direct chemiluminescent technology. Folate in the patient sample competes with acridinium esterlabeled folate in the Lite Reagent for a limited amount of biotin-labeled folate binding protein. Biotin-labeled folate binding protein binds to avidin which is covalently coupled to paramagnetic particles in the Solid Phase. In the ACS:180 Folate assay the sample is pretreated to release the folate from endogenous binding proteins in the sample.
The system performs the following steps for calibrators, quality control samples, and patient samples:
- dispenses 150 uL of sample into a cuvette
- dispenses 50 µL of DTT
- dispenses 100 µL of folate binding protein and 200 µL of Solid Phase and incubates for 5.0 minutes at 37°C
- dispenses 100 µL of Lite Reagent and incubates for 2.5 minutes at 37°C
- separates, aspirates, and washes the cuvettes with reagent water6
- dispenses 300 uL each of Reagent 1 and Reagent 2 to initiate the chemiluminescent reaction
- reports results according to the selected option, as described in the system operating instructions or in the online help system
An inverse relationship exists between the amount of folate present in the patient sample and the amount of relative light units (RLUs) detected by the system.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Expected Results:
To determine the reference range for the ACS:180 Folate assay for serum and RBC folate, data was obtained on 263 serum and 109 red blood cell folate samples, respectively. The normal ranges are based on 95% confidence intervals and the deficient ranges represent the observed ranges.
- Serum folate: 32 deficient samples (Mean: 1.08 ng/mL, Range: 0.0-2.31 ng/mL), 231 normal samples (Mean: 9.89 ng/mL, Range: 4.25-23.8 ng/mL).
- RBC folate: 10 deficient samples (Mean: 64.4 ng/mL, Range: 9-157 ng/mL), 99 normal samples (Mean: 545 ng/mL, Range: 322-886 ng/mL).
Deficient samples were diagnosed by bone and/or peripheral blood smear pathology and other criteria including: megaloblastic anemia, folate deficient diet, malabsorption, alcoholism, Tropical Sprue, abnormal blood parameters including mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and hematocrit (HCT).
Sensitivity and Assay Reportable Range:
The ACS:180 Folate assay measures folate concentrations up to 20 ng/mL (45.4 nmol/L) with a minimum detectable concentration of 0.25 ng/mL (0.6 nmol/L). Analytical sensitivity is defined as the concentration of folate that corresponds to the RLUs that are two standard deviations less than the mean RLUs of 20 replicate determinations of the folate zero standard in 7 assays with 3 lots of reagents.
Method Comparison:
- For 258 serum samples (0 to 20 ng/mL): ACS:180 Folate = 0.92 (alternate chemiluminescent method) + 0.21 ng/mL; Correlation coefficient (r) = 0.95.
- For 189 red blood cell samples (9.0 to 882 ng/mL): ACS:180 RBC Folate = 0.93 (alternate chemiluminescent method) + 52.8 ng/mL; Correlation coefficient (r) = 0.96.
Precision:
Four samples were assayed six times with three lots of reagents in 23 runs on four systems (n = 138 for each sample), over a period of three days.
- Mean Folate 1.91 ng/mL: Within-run % CV = 7.95, Total % CV = 9.24
- Mean Folate 5.94 ng/mL: Within-run % CV = 5.36, Total % CV = 8.79
- Mean Folate 10.6 ng/mL: Within-run % CV = 5.61, Total % CV = 6.60
- Mean Folate 15.4 ng/mL: Within-run % CV = 4.88, Total % CV = 5.36
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1295 Folic acid test system.
(a)
Identification. A folic acid test system is a device intended to measure the vitamin folic acid in plasma and serum. Folic acid measurements are used in the diagnosis and treatment of megaloblastic anemia, which is characterized by the presence of megaloblasts (an abnormal red blood cell series) in the bone marrow.(b)
Classification. Class II.
0
JUN 30 1999
Company Confidential
Summary of Safety and Effectiveness
As required by 21 CFR 807.92, the following 510(k) Summary is provided:
1. Submitters Information
| Contact person: | William J. Pignato
Director of Regulatory Affairs |
|-------------------------|-------------------------------------------------------------------------|
| Address: | Chiron Diagnostics Corporation
63 North Street
Medfield, MA 02052 |
| Phone:
Fax
e-mail | (508) 359-3825
(508) 359-3356
william.pignato.b@bayer.com |
April 30, 1999 Date Summary Prepared:
2. Device Information
| Proprietary Name: | Chiron Diagnostics ACS: 180 Folate |
|---|---|
| Common Name: | Folate Immunological test system |
| Device Classification: | Class II |
3. Predicate Device Information
| Name: | Chiron Diagnostics ACS: 180 Folate Immunoassay |
|---|---|
| Manufacturer: | Chiron Diagnostics Corporation |
4. Device Description
Folate, with vitamin B12, is essential for DNA synthesis, which is required for normal red blood cell maturation. Humans obtain folate from dietary sources including fruits, green and leafy vegetables, yeast, and organ meats. Folate is absorbed through the small intestine and stored in the liver.
Low folate intake, malabsorption as a result of qastrointestinal diseases, pregnancy, and drugs such as phenytoin are causes of folate deficiency. Folate deficiency is also associated with chronic alcoholism. Folate and vitamin B12 deficiency impair DNA synthesis, causing macrocytic anemias. These anemias are characterized by abnormal maturation of red blood cell precursors in the bone marrow, the presence of megaloblasts, and decreased red blood cell survival.
Since both folate and vitamin B12 deficiency can cause macrocytic anemia, appropriate treatment depends on the differential diagnosis of the deficiency. Serum folate measurement provides an early index of folate status. However, folate is much more concentrated in red blood cells than in serum so the red blood cell folate measurement
1
more closely reflects tissue stores. Red blood cell folate concentration is considered the most reliable indicator of folate status.
5. Statement of Intended Use
For the quantitative determination of folate in serum or EDTA plasma and red blood cells using the Folate BA (Biotin Avidin) assay on the Chiron Diagnostics ACS:180® Automated Chemiluminescence Systems.
6. Summary of Technological Characteristics
The Chiron Diagnostics ACS:180 Folate assay is a competitive immunoassay using direct chemiluminescent technology. Folate in the patient sample competes with acridinium esterlabeled folate in the Lite Reagent for a limited amount of biotin-labeled folate binding protein. Biotin-labeled folate binding protein binds to avidin which is covalently coupled to paramagnetic particles in the Solid Phase. In the ACS:180 Folate assay the sample is pretreated to release the folate from endogenous binding proteins in the sample.
The system performs the following steps for calibrators, quality control samples, and patient samples:
dispenses 150 uL of sample into a cuvette
dispenses 50 µL of DTT
dispenses 100 µL of folate binding protein and 200 µL of Solid Phase and incubates for 5.0 minutes at 37°C
dispenses 100 µL of Lite Reagent and incubates for 2.5 minutes at 37°C
separates, aspirates, and washes the cuvettes with reagent water6
dispenses 300 uL each of Reagent 1 and Reagent 2 to initiate the chemiluminescent reaction
reports results according to the selected option, as described in the system operating instructions or in the online help system
An inverse relationship exists between the amount of folate present in the patient sample and the amount of relative light units (RLUs) detected by the system.
6. Performance Characteristics
Expected Results
To determine the reference range for the ACS:180 Folate assay for serum and RBC folate, data was obtained on 263 serum and 109 red blood cell folate samples, respectively. The normal ranges are based on 95% confidence intervals and the deficient ranges represent the observed ranges.
2
Company Confidential
| Category | N | Mean
(ng/mL) | Range
(ng/mL) | Mean
(nmol/L) | Range
(nmol/L) |
|---------------|-----|-----------------|------------------|------------------|-------------------|
| Serum | | | | | |
| folate | | | | | |
| deficient* | 32 | 1.08 | 0.0-2.31 | 2.45 | 0.0-5.24 |
| normal | 231 | 9.89 | 4.25-23.8 | 22.4 | 9.65-54.0 |
| RBC | | | | | |
| folate | | | | | |
| deficient* | 10 | 64.4 | 9-157 | 146 | 20.4-356 |
| normal | 99 | 545 | 322-886 | 1237 | 731-2011 |
- Diagnosed by bone and/or peripheral blood smear pathology and other criteria including:
- megaloblastic anemia
- . folate deficient diet
- malabsorption
- alcoholism ●
- . Tropical Sprue
- . abnormal blood parameters including mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and hematocrit (HCT).
Laboratories should consider these reference ranges as guidelines only. The data was obtained on apparently healthy males and females from the United States. Due to population demographic factors, assay methods, calibration, and reagent specificity, each laboratory should establish its own reference ranges for the diagnostic evaluation of patient results.
Sensitivity and Assay Reportable Range
The ACS:180 Folate assay measures folate concentrations up to 20 ng/mL (45.4 nmol/L) with a minimum detectable concentration of 0.25 ng/mL (0.6 nmol/L). Analytical sensitivity is defined as the concentration of folate that corresponds to the RLUs that are two standard deviations less than the mean RLUs of 20 replicate determinations of the folate zero standard in 7 assays with 3 lots of reagents.
Method Comparison
For 258 serum samples in the range of 0 to 20 ng/mL (0 to 45.4 nmol/L), the relationship between the ACS:180 Folate assay and an alternate folate assay is described by the equation:
ACS:180 Folate = 0.92 (alternate chemiluminescent method) + 0.21 ng/mL Correlation coefficient (r) = 0.95
For 189 red blood cell samples in the range of 9.0 to 882 ng/mL (20.4 to 2002 nmoV/L), the relationship between the ACS:180 Folate assay and an alternate folate assay is described by the equation:
ACS:180 RBC Folate = 0.93 (alternate chemiluminescent method) + 52.8 ng/mL Correlation coefficient (r) = 0.96
3
Precision
Four samples were assayed six times with three lots of reagents in 23 runs on four systems (n = 138 for each sample), over a period of three days. The following results were obtained:
| Mean Folate (ng/mL) | Mean Folate (nmol/L) | Within-run % CV | Total % CV |
|---|---|---|---|
| 1.91 | 4.34 | 7.95 | 9.24 |
| 5.94 | 13.5 | 5.36 | 8.79 |
| 10.6 | 24.1 | 5.61 | 6.60 |
| 15.4 | 35.0 | 4.88 | 5.36 |
4
Image /page/4/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS). The seal features a stylized eagle with three lines forming its body and wings. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
JUN 30 1999
Mr. William J. Pignato Director of Regulatory Affairs Chiron Diagnostics Corporation 63 North Street Medfield, Massachusettes 02052-1688
K991582 Re:
Trade Name: Chiron Diagnostics ACS: 180® Folate Assay Regulatory Class: II Product Code: CGN, JIS Dated: April 30, 1999 Received: May 7, 1999
Dear Mr. Pignato:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
5
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D. M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
Company Confidential
Page | of |
510(k) Number (if known): K991682
Device Name: Chiron Diagnostics ACS:180 Folate Assay
Indications for Use:
For the quantitative determination of folate in serum or EDTA plasma and red blood cells using the Folate BA (Biotin Avidin) assay on the Chiron Diagnostics ACS: 180® Automated Chemiluminescence Systems.
Dean Cooper
(Division Sign-Off)
vision of Clinical Lab ratory Devices 510(k) Number
(PLEASE DO NOT WRITE BELOW THIS LINE--CONTINUE ON ANOTHER PAGE, IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109)
OR
Over-The-Counter Use (Optional Format 1-2-96)